MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma

MYTSYK, Yulian, Yuriy BORYS, Lesia TUMANOVSKA, Dmytro STROY, Askold KUCHER, Katarina GAZDIKOVA, Luis RODRIGO, Peter KRUŽLIAK, Robert PROSECKY, Peter URDZIK and Victor DOSENKO. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma. Clinical and Experimental Medicine. Milan: SPRINGER-VERLAG ITALIA SRL, 2019, vol. 19, No 4, p. 515-524. ISSN 1591-8890. Available from: https://dx.doi.org/10.1007/s10238-019-00574-7.

Basic information

• Original name: MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma
• Authors: MYTSYK, Yulian (804 Ukraine), Yuriy BORYS (804 Ukraine), Lesia TUMANOVSKA (804 Ukraine), Dmytro STROY (804 Ukraine), Askold KUCHER (804 Ukraine), Katarina GAZDIKOVA (703 Slovakia), Luis RODRIGO (724 Spain), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution), Robert PROSECKY (203 Czech Republic), Peter URDZIK (703 Slovakia) and Victor DOSENKO (804 Ukraine).
• Edition: Clinical and Experimental Medicine, Milan, SPRINGER-VERLAG ITALIA SRL, 2019, 1591-8890.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30101 Human genetics
• Country of publisher: Italy
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.644
• RIV identification code: RIV/00216224:14110/19:00111783
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1007/s10238-019-00574-7
• UT WoS: 000491035600013
• Keywords in English: Cancer; Renal cell carcinoma; Clear cell; miRNA-15a; MicroRNA-15a; Biomarker; Genetic; Prediction; Prognosis; Survival
• Tags: 14110121, rivok
• Tags: International impact, Reviewed

Abstract

None of the currently investigated molecular markers demonstrated sufficient accuracy in prognostication of the renal cell carcinoma (RCC) oncologic outcomes; thus, none of them has been recommended for the application in the routine clinical practice. The role of miR-15a as a potential prognostic marker for RCC is still not unveiled. The aim of our study was to assess the expression of miR-15a in tumor tissues of the patients with RCC and to evaluate the possibility of its usage as a prognostic molecular biomarker of this disease. The retrospective included 64 adult patients with clear cell RCC (ccRCC) in whom radical or partial nephrectomy was conducted. After deparaffinization of formalin-fixed paraffin-embedded (FFPE) ccRCC specimens, the tissue expression of miR-15a was measured using the reverse transcription and quantitative polymerase chain reaction in the real time. For the reference, the expression of miR-15a was estimated in 15 FFPE tissue specimens of the normal renal parenchyma. Survival analysis involved all cases of non-metastatic RCCs (n = 57). Five-year cancer-specific survival (CSS) was estimated by means of the Kaplan-Meier method and was calculated from the date of surgery to the date of death. Patients with the RCC were characterized by significantly upregulated tumor tissue mean levels of miR-15a compared to the healthy controls: 0.10 +/- 2.62 relative units (RU) versus 4.84E - 03 +/- 3.11E - 03 RU (p < 0.001). Overexpression of miR-15a was strongly associated with poor histologic prognostic features of ccRCC. Poorly differentiated tumors tend to have more pronounced upregulation of miR-15a compared to highly differentiated lesions: Mean expression values were 4.57 +/- 3.19 RU for Fuhrman grade 4 versus 0.02 +/- 0.01 RU for Fuhrman grade 1 (p < 0.001). The metastatic involvement of the regional lymphatic nodules (N +) was associated with significantly upregulated miRNA-15a in comparison with N - cases: Mean expression values were 4.92 +/- 2.80 RU versus 1.10 +/- 2.29 RU, respectively (p < 0.001). In patients with miR-15a expression in RCC tissues <= 0.10 RU, mean 5-year CSS was significantly longer compared to patients with expression levels above this threshold: 92.31% (mean duration of survival-59.88 +/- 0.12 months) versus 54.8% (mean duration of survival-49.74 +/- 2.16 months), respectively (p < 0.001). The tissue expression of miR-15a could be used as a potential prognostic molecular biomarker for conventional RCC.